Ascendis Pharma: Q2 Blowout Masks a Patent Cloud, But the Franchise Is Moving

YORVIPATH hits blockbuster run-rate, YUVIWEL takes off, and the IP battle with BioMarin looms—but management's conviction is unshaken.

ASND · Earnings Call · 2026-08-13

Quarter in Review: YORVIPATH Hits Its Stride

Ascendis Pharma delivered a strong second quarter, with total product revenue more than doubling year-over-year to EUR 315 million. YORVIPATH, the company's once-daily PTH replacement therapy for hypoparathyroidism, generated EUR 252 million in revenue—already at blockbuster run-rate in its second year on the U.S. market. Management emphasized sustained patient demand and durability of the franchise: “Patients who have successfully initiated YORVIPATH treatment continue to stay on therapy, indicating a high level of satisfaction.” — Jan Mikkelsen, President and Chief Executive Officer · 2026-08-13 The company continues to point to a ex U.S. expansion, with availability now in more than 35 countries, and expects the product to be a core driver for the next decade. This steady-state narrative echoes prior quarters—as Jan said in May, “I don't hide anything. I always want to be transparent.” — Jan Mikkelsen, President and Chief Executive Officer · 2026-05-07

YUVIWEL: A Launch That Exceeds Expectations—and Draws Fire

The real story of the quarter is the launch of YUVIWEL (TransCon CNP) for achondroplasia. In just over four months, the company has enrolled more than 220 patients in the U.S., with a cumulative reimbursement approval rate above 65%. Jan Mikkelsen called it "really a unique launch," and the Rapid uptake is transforming the market: “In the U.S. through June 30, we had more than 170 unique patients enrolled. Since then, uptake has continued with more than 220 enrollment and more than 65% approved for reimbursement in the U.S. through the end of July, really a unique launch.” — Jan Mikkelsen, President and Chief Executive Officer · 2026-08-13 The Rare Disease indication is seeing a paradigm shift, with patients coming from all categories—switchers, re-starters, and the previously treatment-naïve. But the launch is shadowed by an ongoing IP battle with BioMarin. BioMarin has taken the case to the U.S. International Trade Commission, and a first opinion from a single judge is expected in August. Management is confident that the product will remain available, pointing to the public interest and a lack of precedent for blocking a beneficial branded drug. As Jan put it, “I cannot remember one single case in the U.S. where a branded product that provides a benefit to U.S. patients had been denied.” — Jan Mikkelsen, President and Chief Executive Officer · 2026-08-13 That conviction, however, doesn't remove the overhang, and some analysts continue to probe the potential financial impact. The company maintains that any outcome will not materially affect its destiny.

Whatever has happened, it will not have any material impact on Ascendis pathway. I can guarantee that. It's some kind of people take it up as a life and death for Ascendis. This is a total not taken into the perspective what it means for Ascendis.
Jan Mikkelsen, President and Chief Executive Officer · 2026-08-13

Combination Therapy: The Next Frontier

Beyond the monotherapy launch, Ascendis is building a broader franchise around combination treatment with TransCon CNP and TransCon Growth Hormone. The COACH trial continues to show unprecedented improvements in growth velocity, body proportionality, and even arm span. Scott Smith highlighted the magnitude: "The unprecedented improvements in the arm span with combination were plus 9.4 centimeters." The company plans to initiate a Phase III combination trial later this year, aiming to establish a new standard of care in achondroplasia. This ambition has been a long-running theme—management's confidence in the underlying platform was evident in February when, asked about YUVIWEL's approval odds, Jan answered, “Will TransCon CNP be approved? I would say yes.” — Operator, Operator · 2026-02-11 The TransCon technology platform is also fueling a pipeline of new chemical entities, with at least one NCE expected to enter the clinic each year.

Financial Firepower and a Long-Term Vision

The financial transformation is striking. With total revenue of EUR 339 million and non-IFRS operating profit of EUR 92 million, the company is now self-sustaining. Management reiterated its guidance for more than EUR 500 million in operating cash flow this year, and its ambition to reach EUR 5 billion in revenue by 2030. The balance sheet is clean—no convertible debt, no bank debt, and EUR 1.4 billion in equity. What changed this quarter? The launch of YUVIWEL has moved the needle, and the company's confidence in its ex U.S. franchise is palpable. The key question now is whether the IP challenge can derail the momentum. Management's tone suggests it won't, but investors will be watching the ITC process closely. For now, Ascendis is executing on all cylinders, and the market is taking notice.